<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="285">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351243</url>
  </required_header>
  <id_info>
    <org_study_id>KIN-1901-2001</org_study_id>
    <nct_id>NCT04351243</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19.</brief_title>
  <official_title>A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kinevant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kinevant Sciences GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled
      study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute
      respiratory distress syndrome (ARDS) secondary to COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study KIN-1901-2001 will consist of a 2-week treatment period (last dose Day 8, if
      administered) and a 22-week follow-up period, for a total study duration of 24 weeks for each
      subject. A total of 270 subjects (135 subjects per arm) who have a confirmed diagnosis of
      COVID-19 with clinical evidence of acute lung injury or ARDS will be entered into the trial.

      Subjects will receive a high dose of gimsilumab on Day 1 and a low dose of gimsilumab on Day
      8, or matching placebo (saline solution) on Day 1 and on Day 8. The Day 8 dose will be
      omitted if the subject is discharged from the hospital or is no longer in need of
      supplemental oxygen or ventilatory support for &gt;48 hours.

      The primary objective of Study KIN-1901-2001 is to evaluate the impact of IV treatment with
      gimsilumab on mortality in subjects with lung injury or ARDS secondary to COVID-19.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint</measure>
    <time_frame>43 days</time_frame>
    <description>Vital status at Day 43</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint</measure>
    <time_frame>Day 43</time_frame>
    <description>Incidence and duration of mechanical ventilation use during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint</measure>
    <time_frame>Day 43</time_frame>
    <description>Number of days in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint</measure>
    <time_frame>Day 43</time_frame>
    <description>Number of days of inpatient hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Respiratory Distress Syndrome Due to COVID-19</condition>
  <arm_group>
    <arm_group_label>Gimsilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gimsilumab high dose on Day 1 Gimsilumab low dose on Day 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline on Day 1 Normal saline on Day 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gimsilumab</intervention_name>
    <description>Gimsilumab is a fully human monoclonal antibody (mAb).</description>
    <arm_group_label>Gimsilumab</arm_group_label>
    <other_name>KIN-1901</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant female age 18 to 79 years, inclusive

          2. Subject (or legally authorized representative) is able and willing to provide written
             informed consent, which includes compliance with study requirements and restrictions
             listed in the consent form

          3. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other approved
             clinical testing prior to randomization

        Additional inclusion criteria are detailed in the protocol

        Exclusion Criteria:

        Exclusion criteria are detailed in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arnaud Bastien, MD</last_name>
    <phone>(609)-410-2691</phone>
    <email>arnaud.bastien@roivant.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathews, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Puja Dubal</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

